MiniMed Group, Inc. (MMED)
NASDAQHealth CareMedical - Equipment & ServicesSnapshot 2026-09-04
NASDAQHealth CareMedical - Equipment & ServicesSnapshot 2026-09-04
Research Workspace
Put MMED beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
No standing thesis yet — not enough to read.
View ThesisModerate volatility — typically moves about 2% a day.
View RiskNot enough reads yet
MMED's growth relies on the successful commercialization of the MiniMed Flex insulin pump. Revenue grew 16.6% year over year, but the latest earnings report missed expectations. The stock trades at an undefined multiple, with no clear anchor metric available. Analysts suggest the price is roughly in line with the growth forecast. A significant risk is the elevated 86% probability of missing next quarter's earnings. Peer multiples imply a price about 10% above where it trades. This read is provisional.
Trailing returns as of 2026-09-04. MMED is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 14 analysts currently covering MMED (as of Sep 2026).
Based on 7 Wall Street analysts offering 12-month price targets for MMED in the last 4 months.
Continue this research
Compare MMED with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| MMED Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care (broad) — fair value, gap to price, and forward P/E.
Compare the value case
Put MMED next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Commercialize MiniMed Flex insulin pump
Stock price target increase indicates strong sales performance.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $23.29
The last 12 months of price, then the range of analyst 12-month targets from today’s $23.29.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.

Advances: Commercialize MiniMed Flex insulin pump
Strong revenue growth supports commercialization of MiniMed Flex insulin pump.

Advances: Commercialize MiniMed Flex insulin pump
Price target increase reflects confidence in product commercialization.

Advances: Commercialize MiniMed Flex insulin pump
Projected revenue growth supports commercialization of Flex.

New product shipping enhances market position.

Lack of competitive moat raises concerns.